Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estradiol valerate/dienogest.

Keri Wellington1, Caroline M Perry

  • 1Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand. demail@adis.co.nz

Drugs
|February 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Estradiol valerate 2mg/dienogest 2mg effectively treats menopausal symptoms in postmenopausal women. This hormone therapy demonstrated comparable efficacy to other treatments with a manageable bleeding profile.

Area of Science:

  • Endocrinology
  • Gynecology
  • Pharmacology

Background:

  • Menopause is characterized by climacteric symptoms due to declining estrogen levels.
  • Hormone replacement therapy (HRT) is a common treatment for menopausal symptoms.
  • Estradiol valerate/dienogest is an oral HRT formulation.

Purpose of the Study:

  • To evaluate the efficacy and safety of estradiol valerate 2mg/dienogest 2mg for treating climacteric symptoms.
  • To compare estradiol valerate 2mg/dienogest 2mg with other HRT regimens.

Main Methods:

  • A randomized, double-blind, multicenter trial involving 581 postmenopausal women.
  • Treatment duration was 1 year with daily oral administration.
  • Efficacy assessed by Kupperman Index scores and bleeding patterns. Endometrial biopsies were performed.

Related Experiment Videos

Main Results:

  • Estradiol valerate 2mg/dienogest 2mg showed comparable efficacy to estradiol 2mg/estriol 1mg/norethisterone acetate 1mg in reducing climacteric symptoms (78.5% vs 75.0% reduction).
  • The lowest number of days without bleeding was observed with estradiol valerate 2mg/dienogest 2mg (8.7 days).
  • Endometrial biopsy results indicated predominantly atrophic material (90.8%) with no incidence of hyperplasia across treatment groups.

Conclusions:

  • Estradiol valerate 2mg/dienogest 2mg is an effective treatment for climacteric symptoms in postmenopausal women.
  • The formulation offers a favorable bleeding profile and maintains endometrial health.
  • This HRT option provides a viable alternative for managing menopausal symptoms.